AX-0810 — Full data
2026
ProQR plans to present the full dataset from the Phase 1 study of AX-0810, including Cohort 3, at a medical or scientific conference later this year.Source filing
PRQR biotech catalysts & pipeline
PROQR THERAPEUTICS NV · Data as of 2026-09-08
Upcoming catalysts
AX-0810 — Topline data
Late 2026
AX-0810 data from the 9 mg/kg cohort and 12-week follow up from the ongoing Phase 1 study expected by year-end 2026Source filing
AX-0811 — Initial data
Late 2026
AX-0811 initial data in healthy volunteers expected by year-end 2026, pending CTA authorizationSource filing
Axiomer — Initial data
Late 2026
ProQR expects to advance its first programs generated using its AI-enabled discovery approach into the clinic, with a clinical trial application (CTA) anticipated in mid-2026 and initial clinical data anticipated by year-end 2026.Source filing
AX-0422 — Initial data
H1 2027
AX-0422 for MPS I Hurler Syndrome (IDUA) CTA filing for a first-in-patient study anticipated in early 2027 and initial data expected in the first half of 2027Source filing
AX-0422 — IND submission
early 2027
AX-0422 for MPS I Hurler Syndrome (IDUA) CTA filing for a first-in-patient study anticipated in early 2027 and initial data expected in the first half of 2027Source filing
AX-0810 or AX-0811 — Initial data
H1 2027
The Company expects to report initial clinical data from the IIT in the first half of 2027.Source filing
AX-0811 — Initial data
H1 2027
IIT in pediatric biliary atresia in China, with initial data targeted for first half of 2027Source filing
AX-2911 (PNPLA3) — Initial data
H1 2027
AX-2911(PNPLA3) FIH IIT in China expected in the first half of 2027Source filing
AX-0810 or AX-0811 — Interim data
mid-2028
Potentially registration-enabling Phase 2 program, subject to regulatory interactions, expected to start in mid-2027 with first interim analysis data expected by mid-2028Source filing